A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.
from Times of India https://ift.tt/30aDSMa
Subscribe to:
Post Comments (Atom)
-
from Times of India https://ift.tt/3stcMKs
-
मेलबर्न, : भारत आणि ऑस्ट्रेलिया यांच्यातील दुसरा कसोटी सामना २६ डिसेंबरपासून खेळवण्यात येणार आहे. या सामन्यासाठी भारतीय संघामध्ये महत्वाचे...
No comments:
Post a Comment